Guardant Health a target for acquisition?
Who would be the contenders?
Guardant Health GH 0.00%↑ is a prominent precision oncology company that has made significant strides in transforming cancer care through its advanced blood tests. Founded in 2012 by Helmy Elthoukhy and AmirAli Talasaz, the company is headquartered in Redwood City, California. The founders met at Stanford University and later worked together at Illumina ILMN 0.00%↑ before starting GH. Early in its history, the company focused on developing a comprehensive biopsy-free cancer test, which was considered the first of its kind.
GH has reported a strong start of 2024 with a 31% revenue growth in the first quarter, driven by increased clinical and biopharma sales. They’ve also made significant progress with their ECLIPSE clinical trial, which was published in NEJM. The company has launched a service at the Royal Marsden hospital in the UK for testing advanced non-small cell lung cancer (NSCLC) patients.
They recently received approval from the FDA for the Guardant360 CDx liquid biopsy test as a companion diagnostic for certain cancer treatments.